
Oncologist

No OPD information available
Brain Tumor
Glioma
Gliomatosis Cerebri
Astrocytoma
Cerebral Cavernous Malformation
Gamma Knife Radiosurgery
Glioblastoma
HER-2 Positive Breast Cancer
Lung Cancer
Melanoma
Non-Small Cell Lung Cancer (NSCLC)
Mark B. Pinkham is a male healthcare provider who specializes in treating various conditions like brain tumors, lung cancer, and melanoma. He uses advanced techniques like Gamma Knife Radiosurgery to help patients. Mark B. Pinkham is known for his special skills in handling complex cases like Glioblastoma and HER-2 Positive Breast Cancer.
Patients trust Mark B. Pinkham because he communicates clearly and compassionately with them. He takes time to explain treatment options and listens to their concerns. Patients appreciate his caring and supportive approach to healthcare.
Mark B. Pinkham stays updated with the latest medical knowledge by actively participating in research and attending conferences. He is committed to providing the best possible care to his patients by incorporating new findings into his practice.
In his work, Mark B. Pinkham collaborates closely with colleagues and other medical professionals. He values teamwork and believes in a multidisciplinary approach to patient care. His relationships with colleagues are built on mutual respect and a shared dedication to improving patient outcomes.
Mark B. Pinkham's efforts have had a positive impact on many patients' lives. His research on Patient Reported Outcome Measures in cancer care has led to better symptom control and enhanced health service experiences for patients undergoing treatment. Additionally, his participation in clinical trials, like the one on Osimertinib for Non-Small Cell Lung Cancer with brain metastases, has contributed valuable insights to the field of oncology.
Overall, Mark B. Pinkham is a dedicated healthcare provider who is committed to delivering high-quality care to his patients. His expertise, compassion, and commitment to advancing medical knowledge make him a trusted and respected figure in the medical community.
Enrollment Status: Completed
Published: May 31, 2024
Intervention Type: Radiation, Drug
Study Drug: Osimertinib
Study Phase: Phase 2
